Emerald Health Therapeutics’ Wholly Owned Subsidiary Northern Vine to Participate in Series of Cannabis Testing Seminars Ho...
October 09 2018 - 7:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) (“Emerald”) today announced that Northern Vine Canada
Inc. (Northern Vine), a wholly owned subsidiary of Emerald, will
participate in an educational series of seminars regarding
cannabis testing solutions hosted by Thermo Fisher Scientific.
Jaclyn Thomson, PhD, Director of R&D at Northern Vine, will
provide a presentation on pesticide residue and terpenes analysis
methods for the series, called: “Cannabis Testing One-Stop
Analytical Solutions Seminar Series,” across Canada during October
9-18.
The seminar series will provide information to
scientists establishing new cannabis testing laboratory or
scaling-up operations. The series includes four stops in Montreal,
Ottawa, Toronto, and Vancouver. Each seminar will cover: Health
Canada regulation updates, targeted and non-targeted pesticide
analysis, sample preparation tips for improving results, fast and
accurate heavy metal analysis to ppb levels, rapid mycotoxin
analysis, and cannabis potency testing.
“With nationwide legalization on the horizon,
I’m honored to participate in this seminar series to share insights
into how to comply with updated testing regulations for the
Canadian cannabis market,” said Dr. Thomson. “The upcoming legal
marketplace will create new opportunities for laboratories,
licensed producers, and start-ups. Through this series, we hope to
support and prepare these organizations to produce reliable results
and ensure every sample meets regulated safety standards.”
For more information on Thermo Fisher
Scientific’s complete cannabis testing solutions for the legalized
Canadian market, please visit
www.thermofisher.com/CannabisTesting.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH;
OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s
Access to Cannabis for Medical Purposes Regulations and produces
and sells dried cannabis and cannabis oil for medical purposes.
Emerald owns 50% of Pure Sunfarms, which is converting a licensed
existing 1.1 million square foot greenhouse in Delta, BC, and is in
commercial production. It owns Agro-Biotech, a Québec-based
licensed cannabis grower with a 75,000 square foot indoor facility
and is planning to add a 500,000 square foot greenhouse in Metro
Vancouver. Emerald’s team is highly experienced in life sciences,
product development, large-scale agri-business, and marketing, and
is focused on developing value-added cannabis-based products with
potential wellness and medical benefits. Emerald is part of the
Emerald Health group, which is broadly focused on developing
pharmaceutical, botanical, and nutraceutical products that may
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include legalization of nonmedicinal cannabis; production capacity
of various facilities; expansion of facilities; and anticipated
production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024